PARP1 and neoplasm: Early PARP inhibitors 3‐AB and PJ34 were shown to overcome tumor resistance to cisplatin in several cancer types,359, 360, 361 and olaparib was later suggested to enhance the therapeutic effect of cisplatin in lung cancer cells.362, 363